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Abstract
Background: Single-dose nevirapine (sdNVP)—which prevents mother-to-child transmission of HIV—selects non-nucleoside
reverse-transcriptase inhibitor (NNRTI) resistance mutations in the majority of women and HIV-infected infants receiving it.
This open-label, randomised trial examined the efficacy of short-course zidovudine (AZT) and lamivudine (3TC) with sdNVP
in reducing NNRTI resistance in mothers, and as a secondary objective, in infants, in a setting where sdNVP was standard-of-
care.
Methods and Findings: sdNVP alone, administered at the onset of labour and to the infant, was compared to sdNVP with
AZT plus 3TC, given as combivir (CBV) for 4 (NVP/CBV4) or 7 (NVP/CBV7) days, initiated simultaneously with sdNVP in labour;
their newborns received the same regimens. Women were randomised 1:1:1. HIV-1 resistance was assessed by population
sequencing at: baseline, 2, and 6 wk after birth. An unplanned interim analysis resulted in early stopping of the sdNVP arm.
406 pregnant women were randomised and took study medication (sdNVP 74, NVP/CBV4 164, and NVP/CBV7 168). HIV-1
resistance mutations emerged in 59.2%, 11.7%, and 7.3% of women in the sdNVP, NVP/CBV4, and NVP/CBV7 arms by 6 wk
postpartum; differences between NVP-only and both NVP/CBV arms were significant (p,0.0001), but the difference
between NVP/CBV4 and NVP/CBV7 was not (p=0.27). Estimated efficacy comparing combined CBV arms with sdNVP was
85.6%. Similar resistance reductions were seen in infants who were HIV-infected by their 6-wk visit.
Conclusions: A short course of AZT plus 3TC, supplementing maternal and infant sdNVP, reduces emergent NNRTI
resistance mutations in both mothers and their infants. However, this trial was not powered to detect small differences
between the CBV arms.
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Single-dose nevirapine (sdNVP) given to HIV-1 infected
women in labour, followed by a single dose administered to their
infants within 72 h of birth, is the simplest regimen to prevent
intrapartum mother-to-child transmission (MTCT) of HIV-1 [1–
3] and is used extensively in resource-limited settings. However,
NVP has a long half-life, leading to detectable plasma levels for as
long as 3 wk following a single dose [4,5] and is associated with
selection of non-nucleoside reverse-transcriptase inhibitor
(NNRTI) resistance mutations detectable with population se-
quencing in 19%–75% of exposed mothers and 33%–87% of their
infected infants [6–10]. Selection of NNRTI-resistance mutations
has also been described in 17%–45% of mothers who received
sdNVP with a short course of antenatal zidovudine (AZT) [11,12].
The presence of these mutations may reduce the clinical response
to NNRTI-based combination antiretroviral therapy (HAART) in
mothers and infants, especially if initiated less than 6 mo after
exposure to sdNVP [11,13]. In October 2008, the US National
Institutes of Health (NIH) released a press statement reporting
that a randomised trial comparing the efficacy of NVP-based
HAART to ritonavir-boosted-lopinavir HAART in women
previously exposed to sdNVP was terminated early because of
higher rates of virological failure and death in the NVP-based
HAART arm; this finding was accentuated in women with NVP-
resistant HIV (http://www3.niaid.nih.gov/news/newsreleases/
2008/ACTG_5208.htm).
We hypothesised that adding other antiretroviral drugs during
the period of high selection pressure, after exposure to sdNVP,
may prevent the selection of maternal-resistant HIV-1 variants
after exposure to sdNVP. The primary objective of this trial—the
Treatment Options Preservation Study (TOPS)—was to compare
the selection of maternal NNRTI resistance mutations after receipt
of three NVP-containing regimens for prevention of mother-to-
child transmission (PMTCT): sdNVP alone or sdNVP combined
with short courses (either 4 or 7 d) of AZT and lamivudine (3TC),
given as combivir, initiated simultaneously with the dose of NVP
at the onset of labour to mother and continued postpartum. Our
secondary objective was to compare rates of resistance mutations
in infants who received the same study drugs as their mothers but
as individual component suspensions.
Methods
Study Setting and Design
This was an open-label, randomised controlled study conducted
between February 2003 and May 2007 at five sites in South Africa
(listed in the Acknowledgments) where the standard of care for the
PMTCT of HIV-1 at the time of the trial was sdNVP—the
HIVNET 012 regimen given to mothers at the start of labour and
to neonates within 72 h of birth [1]. At the time of enrolment into
the study HAART was not routinely available for pregnant
women as treatment for their own HIV disease. Pregnant women
were assessed at two screening visits after 36 wk of gestation. The
late gestational age at recruitment was chosen to ensure that most
complicated pregnancies including premature labour and delivery
had revealed themselves by then. Pregnant HIV-infected women
were eligible for randomisation if they were $18 y, had plasma
HIV viral loads .2,000 RNA copies/ml, were antiretroviral drug
naı ¨ve, did not have any medical contraindications to NVP, AZT,
or 3TC, and gave written informed consent. The viral load
criterion was to ensure that a baseline genotype could be
performed. Haemoglobin ,7.5 g/dl and elective caesarean
section were exclusion criteria. Elective caesarean section is not
routine for HIV-infected women in the South African public
sector and indications for elective caesarean section would likely be
for an obstetric or medical complication. According to the original
protocol (Text S1), eligible women who had consented antenatally
were randomly assigned at the onset of labour to receive sdNVP
alone or sdNVP with 4 (NVP/CBV4) or 7 (NVP/CBV7) d of AZT
with 3TC initiated at the time of NVP dosing and continued
postpartum. A randomisation sequence maintaining a 1:1:1
balance between treatment arms was generated by the data
management centre and distributed in blocks of six, on blinded
scratch cards to trial sites. Newborns were assigned the same
treatment arm as their mothers. Infant feeding decisions were left
to the mothers following infant feeding counselling [14]. Women
who had provided consent for the study but did not meet the
randomisation criteria received the then standard of care—
sdNVP—as did their infants.
All pregnant women were given an observed dose of 200 mg
NVP orally when in labour. CBV (AZT 300 mg+3TC 150 mg)
dosing was one tablet every 12 h, initiated with NVP. To ensure
that mislaid tablets did not result in poor adherence, mothers in
the NVP/CBV4 and the NVP/CBV7 arms were dispensed 12
and 18 CBV tablets representing a total possible course of 6.5 and
9.5 d, respectively. Women were advised to take them 12 hourly to
complete either 4 or 7 d. Adherence was checked by pill count at
2 wk postpartum. Infants received a sdNVP suspension (2 mg/kg)
and simultaneously commenced AZT oral suspension (Retrovir)
12 mg (1.2 ml) and 3TC oral suspension 6 mg (0.6 ml) every 12 h.
Mothers were requested to give medication to their infants to
complete either 4 or 7 d of therapy. Infant compliance was
checked by comparing bottle-weight prior to initial dispensing with
bottle-weight at the 2-wk postnatal visit, measured by trained study
staff using study-specific calibrated electronic scales.
Follow-up of Women and Children
Mothers and infants were reassessed at 2 d, 2 wk, and 6 wk
following delivery. Whole blood specimens were collected for
plasma quantitative HIV-1 RNA assay (HIV Amplicor monitor
1.5, Roche Molecular Systems) and HIV-1 genotyping (TruGene
HIV-1 genotyping kit and OpenGene DNA sequencing system,
Bayer). The limit of detection of the quantitative HIV RNA assay
was 400 copies/ml. All mothers and/or infants who had
resistance-associated mutations at their 2- and/or 6-wk visit were
followed up at 12, 24, 36, 48, 72, and 96 wk or until no resistance
was detected or until HAART was initiated. The study laboratory
was blinded to treatment allocation.
Data management and adverse event reporting were coordi-
nated by the data management centre at Boehringer Ingelheim,
Randburg, South Africa. The trial was approved by the South
African Medicines Control Council and ethics committees of the
Universities of the Witwatersrand, Pretoria, Kwa-Zulu Natal, and
the Pharma-Ethics Independent Research Ethics Committee. The
trial design was registered in the ClinicalTrials.gov register:
NCT00144183.
Statistical Analysis
The initial sample size of 80 mothers per treatment arm had a
power of 80% to detect a difference with an alpha of 0.05 (two
sided) if either CBV treatment arm decreased emergent maternal
resistance from 20% to 4%. The sample size included an expected
rate of new NNRTI resistance mutations in the NVP-only arm of
20%–30%, on the basis of data from the HIVNET 012 study in
which HIV-1 clades A or D predominated [7]. However, data
describing selection of resistance at double this rate in HIV-1 clade
C-infected women from South Africa exposed to sdNVP were
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Opportunistic Infections (CROI) in San Francisco in 2004. These
data, in conjunction with the potential long term consequence of
NNRTI resistance [11], resulted in an investigator-driven
unplanned interim analysis (at the request of JMc of the Perinatal
HIV Research Unit and performed by the sponsor) in mid-2004 as
there was no data safety management board (DSMB) for this
study. The rate of NNRTI resistance mutations in the NVP-only
arm postpartum was found to have exceeded 50%, so enrolment
into the NVP-only arm was halted after discussions with a
representative of the Medicines Control Council and the Chair of
the local ethics committee.
An amended protocol was then used (see Text S1, S2, S3, S4, S5,
S6, S7, S8 for protocol amendments); enrolment was continued into
the NVP/CBV4 and NVP/CBV7 arms only, using the original
randomisation schedule but rerandomising if the NVP arm
appeared. The sample size was increased to 150 mother infant
pairs per arm (Text 7 Amendment 6); assuming 15% resistance at
wk6 inthe lesseffectivearmwiththemore effective armexpectedto
decrease resistance to 5%. The revised sample size of 150 per
treatment arm had a power of 80% to detect a difference with an
alpha of 0.05 (two sided) if one of the CBV treatment arms
decreased maternal resistance from an expected 15% to 5%. We
report results of all participants (mothers and infants) in all three
arms.
A mother or infant was classified as having new or emergent
NNRTI resistance-associated mutations if an amino acid substitu-
tion was observed during follow-up, at either week 2 or week 6 or
both,atoneofthefollowingreversetranscriptase(RT)codons:98G,
100I, 101E/P, 103N/S, 106A/I/M, 108I, 179D/E, 181C/I/V,
188C/H/L, 190A/C/E/Q/S, 225H, 227L, 230L, 236L, 238N/T,
318F.Forthepurposesofthisstudywedidnotdifferentiatebetween
‘‘high level’’ and other NNRTI resistance mutations. Likewise,
nucleoside analogue reverse transcriptase (NRTI) resistance was
identified on the basis of one or more amino acid substitutions 41L,
44A/D, 62V, 65R, 67N/G, 69D/N/X, 70R, 74IV, 75AI/M/T,
77L, 115F, 116Y, 118I, 151M, 161L, 184I/V, 210W, 215F/Y,
219E/N/Q (Stanford University HIV database, http://hivdb.
stanford.edu/index.html, accessed from 2000 to 2007).
The initial primary analysis was three pair-wise comparisons
(NVP-only versus NVP/CBV4, NVP-only versus NVP/CBV7,
and NVP/CBV4 versus NVP/CBV7) of the proportion of
mothers with new NNRTI resistance-associated mutations by
week 6 between the three treatment arms using Fisher’s exact test.
Estimated efficacy was defined for women who received a CBV
regimen as the proportion of mothers for whom emergent
resistance-associated mutations were prevented [15] combining
all CBV recipients into one group. A Cochran-Armitage test for
trend was used to assess ordered categorical variables.
Maternal secondary endpoints in this study included adverse events,
changes in maternal viral load, and the effect of baseline CD4 on the
development of resistance. Infant-related endpoints were the percent-
age of infants infected with HIV-1, with or without new NNRTI
resistance-associated mutations. Infected infants were classified as
having acquired their HIV-1 infection either intrauterine or intra/
postpartum on the basis of the results of DNA PCR testing [16].
Results
750 pregnant women were screened for inclusion into the trial
(Figure 1) starting in February 2003, of whom 181 (24%) did not meet
the entry criteria, the majority (144) of this group because their viral
load was below 2,000 copies/ml. 162 women were not randomised
during labour for the following reasons: they either delivered before
randomisation or not at the study site (89), had elective caesarean
section (32), or received nontrial NVP (19). 407 women were
randomised from March 2003 to November 2005, 406 of whom took
trial medication. Their median age was 27 y (interquartile range
[IQR] 24–30), median CD4 count was 318 cells/mm
3(IQR 212–425),
and median screening HIV RNA viral load was 27,100 copies/ml
(IQR 8,130–74,200) (Table 1). There were 376 mothers (92.4% of
randomised) with follow-up information at 6 wk; no participants were
omitted from the 6-wk analysis other than those lost to follow-up or
with no postpartum genotypic results. Four NVP-only, four NVP/
CBV4, and six NVP/CBV7 did not return for any follow up visits;
their viral load and CD4 counts were similar to the women that did
return. There was no sequencing data on another 17 women, all of
whom were in the CBV-containing arms; 14 had viral loads ,400
copies/ml and the samples provided by the remainder were either
insufficient or unable to be amplified. There were 413 live births and
two stillbirths.Among the live births,there were eight sets of twins.One
intrauterine death was detected after randomisation but before receipt
of treatment, leading to the mother not being treated.Two infants were
unable to take study medication because of birth asphyxia (both in the
NVP/CBV4 arm). The 411 infants who received medication had a
median weight of 3.0 kg (IQR 2.9–3.4 kg) and a median length of
50 cm (IQR 48–52 cm); 48.9% were female (Table 1). HIV-1 clade C
was detected in 98.3% (399/406) of pregnant women, and 12 (3%; 12/
393;95%confidence interval [CI] 2%–5%) had an NNRTI resistance-
associated mutation immediately prior to receipt of NVP; one woman
in the NVP-only arm, eight in the NVP/CBV4 arm, and three in the
NVP/CBV7 arm. Of these women, 11 had one NNRTI resistance-
associated mutation (two A98G, two V101E, two K103N, one
V106IM, one 108I, two V179D, one M230L) and one had V106M,
Y181C, and G190A. Sequencing for resistant mutations immediately
p r i o rt or e c e i p to fN V Pd i dn o ty i e l dar e s u l ti n1 4m o t h e r s( 3 . 4 %o f
mothers tested), their median viral load was 539 copies/ml
(IQR,400–17,300 copies/ml).
Selection of Maternal NNRTI Resistance Mutations
The NVP-only, NVP/CBV4, and NVP/CBV7 regimens were
administered to 75, 163, and 168 women, respectively, of whom
71 (95%), 154 (95%), and 151 (90%) had follow-up visits and
sequence results at 2 and 6 wk postnatally. Only eight of all the
resistance mutations looked for were able to be sequenced in the
postnatal specimens (Table 2); the remaining were either present
at proportions below the limit of detection or were not present at
all. New NNRTI resistance-associated mutations were detected at
2 wk, at 6 wk, or at both visits in 59.2% (42/71; 95% CI 46.8%–
70.7%), 9.7% (15/154; 95% CI 5.1%–14.4%), and 7.3% (11/151;
CI 3.7%–12.7%) of these women, respectively.
Most mothers receiving CBV took more than the prescribed
number of doses as they all were dispensed two additional days of
study drug; in the NVP/CBV4 treatment arm women took a
median of nine doses (IQR 8–11), their median maternal CBV
adherence was 113% (IQR 100%–133%); and in the NVP/CBV7
treatment arm women took a median of 15 doses (IQR 14–17),
their adherence was 107% (IQR 100%–114%). However, when
women with CBV adherence of ,75% or .125% are excluded,
resistance rates remain unchanged compared to those including
these women: 10.7% (11/103; CI 6%–18%) for NVP/CBV4 and
6.3% (9/144; CI 3%–11%) for NVP/CBV7. An as-treated
analysis, restricted to women who received CBV, suggested no
relationship between the number of doses of CBV taken and the
selection of resistance (permutation test, p=0.3305).
On the basis of the 59.2% rate of resistance emergence in the
NVP-only arm, the expected number of mothers with emergent
resistance in the NVP/CBV4 arm and NVP/CBV7 arm was
AZT+3TC to Reduce NVP Resistance
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Maternal and Infant Characteristics NVP, n=75 NVP/CBV4, n=163 NVP/CBV7, n=168 All, n=406
Maternal characteristics at enrolment
Black African 75 (100%) 161 (98.8%) 168 (100%) 404 (99.5%)
Median age in years (IQR) 26 (23–30) 27 (24–31) 26 (23–30) 27 (24–30)
Mean weight in kg (SD) 74.5 (13.6) 75.3 (12.9) 77.8 (14.4) 76.2 (13.7)
Infected with HIV subtype C 74 (98.7%) 159 (97.5%) 166 (98.8%) 399 (98.3%)
Median viral load in copies/ml (IQR) 27,900 (6,800–79,200) 23,950 (6,315–77,950) 30,100 (11,300–67,200) 27,100 (8,130–74,200)
Median CD4 count in cells/mm
3 (IQR) 347 (198–434) 309 (211– 408) 331 (233–423) 318 (212–425)
Emergency caesarean section 17 (22.7%) 31 (19.0%) 49 (29.2%) 97 (23.9%)
Infant characteristics at birth
Live births 77 164 170 411
Gender - girls 39 (50.6%) 80 (48.8%) 82 (48.2%) 201 (48.9%)
Median weight kg (IQR) 3.0 (2.9, 3.3) 3.0 (2.9, 3.4) 3.0 (3.0, 3.5) 3.0 (2.9, 3.4)
Median length cm (IQR) 50 (48, 51) 50 (48, 52) 51 (48, 53) 50 (48, 52)
CBV, AZT plus 3TC administered to mothers and their new born infants for either 4 or 7 d; NVP, sdNVP administered to mothers and their new born infant; SD, standard
deviation.
doi:10.1371/journal.pmed.1000172.t001
Figure 1. CONSORT diagram of the trial. Screening was while women were pregnant and randomisation was during labour (CBV, 3TC with AZT).
doi:10.1371/journal.pmed.1000172.g001
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emergence correspond to 80.5% and 87.8% efficacy in preventing
emergence of resistance, respectively. Comparing the NVP arm to
the combined CBV arms the estimated efficacy is 85.6%.
Mutation-specific efficacy was over 90% for both leading
mutations: K103N and Y181C.
The pattern of emergent mutations was altered by use of CBV
(Table 2): 106M was the second leading mutation with the selection
of relatively uncommon mutations at 101, and 108 which were not
seen with NVP alone. Furthermore, after NVP-only, 60% (25/42;
CI 43%–74%) of the mothers with mutations at 2 and/or 6 wk had
three or more different NNRTI mutations. Whereas, 19% (5/26;
95% CI 7%–39%) of those with mutations after NVP/CBV4 or
NVP/CBV7 had three or more different NNRTI mutations
(Cochran-Armitage trend test, p=0.001). One woman in the
NVP/CBV7 arm had a new mutation associated with 3TC
resistance at RT codon 184, detected by population sequencing at
week 6 but not at week 12. This was the only nucleoside analogue
reverse-transcriptase resistance mutation detected.
After the 6-wk visit, follow-up of women with resistance mutations
continued until NNRTI mutation-free virus was documented. The
last study follow up visit was in January 2007. Fading of NNRTI
resistance mutations appeared to occur more rapidly in women who
received NVP/CBV7 than NVP/CBV4 (Table 3). At 12 wk
postpartum, 62% of NVP-only women who had NNRTI resistance
mutations at 6 wk retained their NNRTI resistance, whereas 34% of
the women who received one of the NVP/CBV regimens and who
had NNRTI resistance at 6 wk retained resistance at 12 wk (Fisher’s
exact test, p=0.04). At 24 and 48 wk the results are similar, but there
were few women at these two time points.
Maternal Viral Load
The median maternal viral load in labour, prior to receipt of
study medication, was 27,900 copies/ml, 23,950 copies/ml, and
30,100 copies/ml for the three treatment arms, NVP, NVP/
CBV4, and NVP/CBV7, respectively. HIV RNA was modestly
reduced by day 2 and reached an observed median nadir at day 14
with counts of 7,650 copies/ml for NVP-only, 421 copies/ml for
NVP/CBV4, and ,400 copies/ml for NVP/CBV7. However, by
the 6-wk visit median maternal HIV RNA levels were similar to
those at baseline: 33,600 copies/ml, 28,600 copies/ml, and 33,850
copies/ml for the NVP-only, NVP/CBV4, and NVP/CBV7 arms,
respectively.
Maternal Baseline CD4 and Emergent NNRTI Resistance
One-fifth of the women recruited into this trial (21%, 85/406,
95% CI 17%–25%) had CD4 cell counts of #200 cells/ml. We
compared emergent resistance rates by whether baseline CD4 was
#200 or .200 cells/ml using the Fisher’s exact, two-sided test:
NVP arm, 82.4% (14/17) versus 48% (24/50), p=0.02; NVP/
CBV4 arm, 25.8% (8/31) versus 5.5% (6/110), p=0.003; NVP/
CBV7 arm, 10.3% (3/29) versus 5.4% (6/112), p=0.39.
Efficacy in Preventing MTCT
The overall, combined intra-uterine and peri/postpartum HIV
transmission rate by the 6-wk visit was 12.2% (49/403; CI 9.3%–
15.7%). The majority of infants with HIV-1 infection were HIV-1
positive when first tested within a day of delivery (HIV DNA- and
RNA-positive) and confirmed-infected at follow-up (43/403
infants; 8/76 NVP-only, 25/161 NVP/CBV4, 10/166 NVP/
CBV7), suggesting in utero HIV acquisition. Three additional
infants were HIV-1 infected when first tested at 2–6 wk of age, all
in the NVP/CBV7 arm and three were HIV-negative initially, but
positive at 6 wk.
Infants Developing NNRTI-Resistant Mutations
In the infants with intra-uterine HIV-1 infections and follow-up
after exposure to antiretrovirals, NNRTI-resistant mutations were
seen in seven of the eight HIV-infected infants treated with NVP-
only, four of 25 of those who received NVP/CBV4, and none of
the ten who received NVP/CBV7. The difference between NVP
alone and the combined NVP/CBV arms is statistically significant
(Fisher’s exact, two-sided, p,0.001). No mother-infant pair
developed identical NNRTI-resistant mutations.
Table 2. New resistance mutations by study arm with estimated efficacy of preventing NNRTI resistance mutations in women who
received either the 4 or 7 d of AZT plus 3TC (CBV4/7) treatment arms compared to those exposed to sdNVP alone.
Study Arm NNRTI Resistance Mutation Codon
Women with New
NNRTI Resistance
Mutations (95%
CI)
98 101 103 106I 106A 106M 108 181 188 190
NVP, n=71 1 (1.4%) 0 31 (43.7%) 21 (29.6%) 10 (14.1%) 13 (18.3%) 0 28 (39.4%) 19 (26.8%) 14 (19.7%) 42
59.2% (46.8–70.7)
NVP/CBV4, n=154 0 0 7 (4.5%) 8 (5.2%) 0 8 (5.2%) 1 (0.6% 4 (2.6%) 4 (2.6%) 3 (1.9%) 15
9.7% (5.1–14.4)
NVP/CBV7, n=151 1 (0.7%) 3 (2.0%) 4 (2.6%) 3 (2.0%) 1 (0.7%) 2 (1.3%) 0 4 (2.6%) 1 (0.7%) 4 (2.6%) 11
7.3% (3.7–12.7)
Combined CBV
arms, n=305
1 (0.3%) 3 (1.0%) 11 (3.6%) 11 (3.6%) 1 (0.3%) 10 (3.3%) 1 (0.3% 8 (2.6%) 5 (1.6%) 7 (2.3%) 26
8.5% (5.6–12.2)
Estimated
efficacy
a (95% CI)
— — 91.7%
(84.5–95.6)
87.8%
(76.1–93.8)
97.7%
(86.1–99.6)
82.1%
(61.2–91.6)
— 93.3%
(86.2–96.8)
93.9%
(84.6–97.6)
88.4%
(72.8–95.0)
85.6%
(78.2–90.5)
b
aEstimated efficacy was calculated by comparing the expected rate of new resistance mutations based on the actuals in the NVP arm with the observed rate in the
combined CBV arms. For codons where the number was #1, no efficacy calculation was done.
bOverall efficacy.
doi:10.1371/journal.pmed.1000172.t002
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Three maternal deaths occurred and all received NVP/CBV4.
The deaths occurred at 4, 9, and 12 mo after delivery and all were
caused by respiratory disease; tuberculosis was suspected in the
deaths of two of the three women. Both of the participants who
died of suspected TB had CD4 counts of ,100 cells/mm
3 at the
time of screening, one woman had been treated for tuberculosis for
4 mo prior to her death.
Duringthe antenatalscreening period, beforeanystudy drug had
beenadministered,one-thirdofthemotherssufferedadverseevents.
The most common events during this period were urinary tract
infections. Pregnancy-induced hypertension occurred in ten (2.5%)
mothers, two of whom were diagnosed with pre-eclampsia.
Following randomisation and delivery the most common adverse
eventswerealsoinfections:4%(3/70),6.7%(11/163),and4.2%(7/
168) for the NVP-only, NVP/CBV4, and NVP/CBV7 arms,
respectively. Postpartum sepsis was diagnosed in 1.3% (1/70), 3.1%
(5/163), and 2.4% (4/168) for the NVP-only, NVP/CBV4, and
NVP/CBV7 arms, respectively. Suspected adverse drug reactions
were reported in 2.5% (10/406) of mothers and were limited to the
combination arms, 1.8% in NVP/CBV4 arm (3/163), and 4.2% in
NVP/CBV7 arm (7/168); none were severe. Rashes were reported
for six women, for one of them a relationship to NVP use was
considered possible. The most common abnormal laboratory tests
were below normal haemoglobin and above normal aspartate
aminotransferase (AST) levels; there were 24, 55, and 56 women in
the NVP, NVP/CBV4, and NVP/CBV7 arms, respectively, whose
AST levels were elevated above normal. However, there were no
hepatic adverse events reported. There were no significant trends
associated with CBV use.
Serious adverse events were observed in 4.9% of mothers during
the screening period and in 8.1% of mothers after randomisation.
During the screening phase these events were primarily pregnancy
and perinatal conditions (31/37), whereas infections were the
majority after randomisation (21/33).
Infant Safety
There were 13 infant deaths (3.2%; 95% CI 2%–5%); ten were
HIV-infected, three in the NVP-only arm, five in the NVP/CBV4
arm, and two in the NVP/CBV7 arm. The causes of death in the
HIV-infected infants were either gastroenteritis or respiratory
infections; the oldest child to die in this group was 10 mo old.
Three HIV-negative infants died, one from congenital pneumonia
(NVP-only arm), one from complications of trisomy 18 (NVP/
CBV4 arm), and one sudden infant death (NVP/CBV4 arm)
without any preceding illness at 37 d after delivery. Suspected
drug-related reactions were reported in 1.2% of infants (5/411).
The events were hyperamylasaemia in the NVP-only arm (1/77),
abdominal pain and vomiting in the NVP/CBV4 arm (2/164),
and vomiting and jaundice in the NVP/CBV7 arm (2/170). The
jaundice in the NVP/CBV7 arm was classified as serious. The
most common abnormal laboratory tests were below-normal
haemoglobin and above-normal bilirubin levels. There were no
significant trends associated with CBV use.
Discussion
This study shows that the addition of short course AZT and
3TC (for either 4 or 7 d) to sdNVP, initiated at the same time as
the dose of NVP for PMTCT in antiretroviral-naı ¨ve pregnant
women and their infants, results in a reduction in the proportion of
mothers with new NNRTI-resistant mutations, when measured at
2 and 6 wk postdelivery. The nature of these mutations was also
altered with fewer emergent mutations per woman being found. A
reduction was also demonstrated in new NNRTI-resistant
Table 3. Long-term follow-up of women with emergent NNRTI mutations detected 2–6 wk after exposure to sdNVP during labour.
Arm Resistance and Visit Outcome Weeks after delivery
12 24 48
NVP 42/71 women with emergent mutations
at 6 wk
No resistance detected 11 24 31
Resistance mutation(s) detected 26 13 5
Total women tested at that visit 37 37 36
Resistance mutation(s) detected at prior visit
but lost to follow up at this visit
55 6
Total potentially with resistance mutations 31 (43.7%) 18 (25.4% 11 (15.5%
NVP/CBV4 18/154 women with emergent
mutations at 6 wk
No resistance detected 6 9 6
Resistance mutation(s) detected 2 1 1
Total women tested at that visit 8 10 7
Resistance mutation(s) detected at prior visit
but lost to follow up at this visit
75 5
Total potentially with resistance mutations 9 (5.8%) 6 (3.9%) 6 (3.9%)
NVP/CBV7 11/151 women with emergent
mutations at 6 wk
No resistance detected 4 9 9
Resistance mutation(s) detected 5 1 0
Total women tested 9 10 9
Resistance mutation(s) detected at prior
visit but lost to follow up at this visit
21 2
Total potentially with resistance mutations 7 (4.6%) 2 (1.3%) 2 (1.3%)
doi:10.1371/journal.pmed.1000172.t003
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both mothers and infants and the majority of deaths (100% for
mothers and 78% for infants) were HIV-related. Of HIV-infected
infants who died, all were in utero infections.
The 4 and 7 d AZT plus 3TC with sdNVP combination
regimens in this study were similarly efficacious in preventing
emergence of resistance in the 6 wk after NVP exposure: 80.5% in
the NVP/CBV4 arm and 87.8% in the NVP/CBV7 when
compared to NVP-only. However, 7 d of NVP/CBV resulted in
an earlier return to wildtype virus than the shorter course. The
presentation in 2004 of preliminary results of this study,
demonstrating a significant reduction in the selection of resistance
compared to NVP alone, prompted the inclusion of a short course
CBV regimen in the World Health Organisation guidelines for the
management of pregnant HIV-infected mothers [17].
NNRTI resistance selected after sdNVP regimens [18] appears
to compromise the response to NVP-based HAART, especially if
started soon after the initial NVP exposure [11,13]. Women whose
baseline CD4 count was #200 cells/mm
3 were particularly prone
to selection of resistance mutations.
In this study both CBV regimens were adhered to and were easy
to provide and could be considered as additions to sdNVP for
PMTCT in countries where more complex or longer PMTCT
prophylactic regimens are not feasible. The optimal length of
postpartum cover of the prolonged NVP ‘‘tail’’ is not known, it is
possiblethat additionalbenefit maybe obtained from longercourses
of antiretroviral agents, given the length of persistence of NVP
following a single dose [4]. However, two subsequent studies have
supported a short course ‘‘tail cover’’ approach [19,20]. In the
Zambian study, the addition of one dose of tenofovir and
emtricitabine to the maternal intrapartum NVP dose reduced
selection of NNRTI resistance by 53% [21]. Women in the
Zambian trial with CD4+ cell counts less than 200/mm
3 were
excluded so they could be treated with HAART and all participants
received antepartum AZT in addition to intrapartum NVP.
None of the mother-infant pairs in this trial had access to
prophylaxis for in utero transmission of HIV-1, which was not
available at the time in South Africa. The high in utero HIV-1
transmission rate we report supports the use of interventions
earlier in pregnancy to prevent this. Combination antiretroviral
therapy during pregnancy has decreased HIV-1 MTCT trans-
mission in well-resourced settings to ,2% [22]. The correlation
between baseline CD4 and development of NNRTI-resistant
mutations we report supports the initiation of HAART during
pregnancy in women with low CD4 counts, in line with World
Health Organisation and other national and international
guidelines. SdNVP with 4 or 7 d of CBV, as used in this study,
suppressed HIV viral loads to ,400 copies/ml in the majority of
mothers at 7–10 d after the final dose, but the viral load had
returned to pretreatment levels by 6 wk postpartum.
The limitations of this study include that it was conducted in
predominantly HIV clade C-infected participants in South Africa,
although NNRTI resistance has been shown to be more common
following sdNVP with this rather than other clades [23]. The
exclusion of women with viral loads of less than 2,000 copies/ml
may have resulted in a greater effect of CBV in preventing
resistance mutations than if all women were randomised
irrespective of their viral load. Furthermore, by chance, there
were higher rates of baseline resistance in the CBV4 group than in
the other groups. We used a relatively insensitive method of
detecting resistance; use of more sensitive methods able to detect
minority populations of resistant virus [9,24], arguably may show
less of an effect if higher rates of resistance were to be found in all
arms. None of the women we included in this study had received
AZT prior to receipt of study drugs; we are therefore unable to
show the combined effect of several weeks of AZT given prenatally
in conjunction with sdNVP and 4 or 7 d of AZT plus 3TC started
at the onset of labour. Finally, the study was not powered to
discriminate between rates of resistance we found in the two CBV-
containing arms.
This trial, however, provides clear evidence that the selection of
HIV-1 NNRTI resistance mutations by sdNVP can safely be
reduced in mothers and HIV-infected infants by the addition of 4
or 7 d of AZT plus 3TC started at the time of the NVP dose.
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Background. Currently, about 33 million people are
infected with the human immunodeficiency virus (HIV),
which causes AIDS. HIV can be treated with combination
antiretroviral therapy (ART), commonly three individual
antiretroviral drugs that together efficiently suppress the
replication of the virus. HIV infection of a child by an HIV-
positive mother during pregnancy, labor, delivery, or
breastfeeding is called mother-to-child transmission
(MTCT). In 2007, an estimated 420,000 children were newly
infected with HIV, the majority through MTCT. Most of these
mothers and children live in sub-Saharan Africa where child
and maternal mortality rates are high and mortality in HIV-
infected children is extremely high. MTCT is preventable and
there is a global commitment, agreed at the UN General
Assembly Session on HIV/AIDS in 2001, to reduce the
proportion of infants infected with HIV by 50% by 2010.
Why Was This Study Done? In many resource-limited
settings, MTCT is prevented by giving a single dose of
nevirapine (an antiretroviral drug which has a long duration
in the body and protects the fetus during labor and delivery
only) to HIV-infected women in labor and also to a baby
within 72 hours of birth. However, nevirapine, a non-
nucleoside reverse-transcriptase inhibitor (NNRTI), which
suppresses the replication of the virus, is associated with
increased resistance of HIV, in mother and child, to NNRTI.
This resistance reduces the effectiveness of future treatments
of both mother and child with combination ART that
includes an NNRTI; such regimens are the mainstay for
long-term treatment of HIV in developing countries. The
researchers investigated whether giving other antiretroviral
drugs with nevirapine, during labor and delivery, to both
mother and her newborn reduced the chances of them
developing resistance to NNRTIs.
What Did the Researchers Do and Find? The researchers
selected 406 HIV-positive pregnant women for study across
five sites in South Africa between February 2003 and May
2007. The women and their newborn babies were randomly
assigned to receive, either (i) a single dose of nevirapine, (ii) a
single dose of nevirapine plus combivir (zidovudine
combined with lamivudine) for four days, or (iii) a single
dose of nevirapine plus combivir for seven days. At two days,
two weeks, and six weeks after delivery blood was collected
from mothers and babies. HIV virus from blood samples was
analyzed for resistance mutations, and mothers and children
with resistance mutations were monitored for a further 96
weeks until no resistance was detected or combination ART
(also called ‘‘HAART’’) was started. Enrollment into the single-
dose nevirapine arm was stopped early because a very high
rate of NNRTI resistance mutations was found and other
investigators reported long-term bad consequences of
NNRTI-resistance on subsequent ART. The two nevirapine
plus combivir arms were continued. The researchers found
that selection of resistance mutations by single-dose
nevirapine was reduced in mother and child by the
addition of zidovudine and lamivudine for a short period;
resistance mutations were found in 59.2% of women who
got nevirapine only but only 11.7%, and 7.3% of women
treated nevirapine plus four days combivir, and nevirapine
plus seven days combivir respectively. A reduction was also
seen in new NNRTI resistant mutations in the HIV-infected
infants that received combivir. The study did not have
enough women to show that there was a real difference
between the resistance in the four-day and seven-day
combivir regimens.
What Do These Findings Mean? These findings show
that a short-course treatment of zidovudine and lamivudine
in addition to a single dose of nevirapine during labor and
birth reduces the selection of NNRTI resistance mutations in
both mother and child. The drug regimens appeared safe,
and easy to provide and adhere to. Preliminary results from
this study contributed to a change in clinical practice for the
care of pregnant women with HIV; in 2004 the World Health
Organisation guidelines introduced a short course of
combivir with nevirapine for the management of pregnant
HIV-infected women. However, the study had some
limitations. It used HIV-positive women who were mainly
infected with a subtype of HIV called HIV-1 clade C and who
had a lot of virus in their blood. NNRTI resistance after
treatment with nevirapine is more common in clade C than
in others and this study does not address the effect of these
combinations for preventing NNRTI resistance in other HIV
subtypes. Also, World Health Organization, national, and
international guidelines recommend combination ART
during pregnancy, as it decreases HIV transmission from
mother to child in the uterus to ,2% in resource-limited
settings. Although long-term combination treatment may
not be available in all locations, this study does not tell us
how the short-term combinations during and after delivery
tested would compare to longer-term combinations given to
pregnant women in reducing both HIV transmission and HIV
drug resistance.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000172.
N This study is further discussed in a PLoS Medicine
Perspective by Lehman et al.
N The US Centers for Disease Control and Prevention provide
information for HIV treatment and prevention
N MedlinePlus provides extensive information on symptoms
and treatment for HIV/AIDS as well as access to related
clinical trials and medical literature
N aidsmap, a nonprofit, nongovernmental organization
provides information on HIV and supporting those living
with HIV
N The World Health Organization gives information on the
prevention of mother-to-child transmission of HIV
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